FBLG vs MMC · $24.0M cap vs P/E 22, rev $24.46B
FibroBiologics, Inc. Common Stock (FBLG) versus Marsh & McLennan Companies Inc (MMC) — a side-by-side from cached financials, not a winner call.
FibroBiologics, Inc. Common Stock (FBLG) is a biotechnology company listed on US.
Marsh & McLennan Companies Inc (MMC) is a insurance brokers company listed on US.
FBLG does not have a complete income-statement cache yet.
Latest reported MMC revenue for 2024-12-31 was $24.46B. Net income was $4.12B. Revenue was up 7.6% from 2023-12-31 to 2024-12-31. MMC currently screens at market cap $89.82B and trailing P/E 21.9.
FBLG currently screens at market cap $24.0M. MMC currently screens at market cap $89.82B and trailing P/E 21.9.
Not investment advice. Open the FBLG and MMC stock pages for the full models.
Not investment advice.